semaglutide and hair loss in women A new study suggests that may also be responsible for patients who take the drugs GLP-1 therapies and hair loss:

In patients with Polycystic Ovary Syndrome, to what extent do you feel that the benefits of GLP-1 receptor agonists are attributable to weight loss (versus their direct effects on insulin resistance, androgen levels, and ovarian function)

Eli Lilly and Company is currently researching a dual agonist called tirzepatide, which has outperformed semaglutide in phase 3 clinical trials

There were minor reductions in appetite and some weight loss, as is typical with this class of drug

Request a comprehensive panel from your provider: TSH and free T4 (thyroid), fasting glucose, fasting insulin, HbA1c, and cortisol if symptoms warrant it